Corporate Profile

Incyte’s mission is to become one of the leading global oncology companies.

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology.  For additional information on Incyte, please visit the Company’s website at

Recent News More >>
October 02, 2015Data at SITC Annual Meeting to Highlight Progress of Incyte’s Immuno-oncology Portfolio
Results of a proof-of-concept study of epacadostat, Incyte’s IDO1 inhibitor, in combination with pembrolizumab to be presented as a late-breaking abstract WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 2, 2015-- Incyte Corporation (Nasdaq:INCY) announces that new data from its investigational immuno-oncology portfolio will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 30th Anniversary Annual Meeting & Associated Programs... 
Printer Friendly Version
September 29, 2015Baricitinib Superior to Methotrexate in Reducing Signs and Symptoms in Pivotal Phase 3 Study in Patients with Rheumatoid Arthritis
INDIANAPOLIS, Sept. 29, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced positive top-line results of RA-BEGIN, the third Phase 3 study evaluating the safety and efficacy of baricitinib, an investigational medicine for patients with moderately-to-severely active rheumatoid arthritis (RA). The study met its primary objective of demonstrating non-inferiority of baricitinib monotherapy to methotrexate monotherapy based on ACR20 response ra... 
Printer Friendly Version
September 15, 2015Incyte to Present at the Leerink Partners Inaugural Immuno-Oncology Roundtable Conference
WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 15, 2015-- Incyte Corporation (Nasdaq: INCY) announced today it will present at the Leerink Partners Inaugural Immuno-Oncology Roundtable Conference on Thursday, October 1, 2015 at 3:15 p.m. (EDT) in New York. The presentation will be webcast live and can be accessed at under Investor Relations, Events and Webcasts. Investors interested in listening to the live webcast should log on before th... 
Printer Friendly Version

2014 Annual Report
2014 Annual Report Download Documentation

2014 10-K

Notice To Readers: Incyte's press releases, presentations and printed remarks are included on this Web site for historical purposes only. The information contained in these documents and webcasts should be considered accurate only as of the date of the relevant document or presentation. This information may change over time; therefore, visitors to this Web site should not assume that the information contained in these documents or presentations remains accurate at a later time. We do not have any current intention, and expressly disclaim any obligation, to supplement, update or revise any of the information in these documents or presentations.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.